MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes

Oncotarget

Volumn 7, Issue 15, 2016, Pages 19601-19609

  Zhong, Shanliang ^a   Chen, Xiu ^a   Wang, Dandan ^a   Zhang, Xiaohui ^a   Shen, Hongyu ^a   Yang, Sujin ^a   Lv, Mengmeng ^a   Tang, Jinhai ^a   Zhao, Jianhua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast; Cancer; Chemoresistance; MicroRNA; Microvesicles

Indexed keywords

DOCETAXEL; EPIRUBICIN; MICRORNA; MICRORNA 1246; MICRORNA 1268A; MICRORNA 138 5P; MICRORNA 139 5P; MICRORNA 140 3P; MICRORNA 149 3P; MICRORNA 197 3P; MICRORNA 210 3P; MICRORNA 3178; MICRORNA 423 5P; MICRORNA 4258; MICRORNA 4298; MICRORNA 4443; MICRORNA 4644; MICRORNA 574 3P; MICRORNA 6780B 3P; MICRORNA 7107 5P; MICRORNA 744 5P; MICRORNA 7847 3P; NAVELBINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TAXOID; VINBLASTINE; VINORELBINE TARTRATE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL LINE; CANCER RESISTANCE; CANCER STAGING; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; EXOSOME; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; MICROARRAY ANALYSIS; MIDDLE AGED; UPREGULATION; ANALOGS AND DERIVATIVES; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; ELECTRON MICROSCOPY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; EXOSOMES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; MICRORNAS; MICROSCOPY, ELECTRON; TAXOIDS; VINBLASTINE;

EID: 84964720764     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7481     Document Type: Article

References (23)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64:252-271.
3. Rivera E and Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res. 2010; 12:S2.
4. Zhang X, Yuan X, Shi H, Wu L, Qian H and Xu W. Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015; 8:83.
5. Chen WX, Cai YQ, Lv MM, Chen L, Zhong SL, Ma TF, Zhao JH and Tang JH. Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs. Tumour Biol. 2014; 35:9649-9659.
6. Chen WX, Zhong SL, Ji MH, Pan M, Hu Q, Lv MM, Luo Z, Zhao JH and Tang JH. MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer. Tumour Biol. 2014; 35:2883-2892.
7. Yu DD, Wu Y, Shen HY, Lv MM, Chen WX, Zhang XH, Zhong SL, Tang JH and Zhao JH. Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci. 2015; 106:959-964.
8. Chen WX, Liu XM, Lv MM, Chen L, Zhao JH, Zhong SL, Ji MH, Hu Q, Luo Z, Wu JZ and Tang JH. Exosomes from drugresistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS One. 2014; 9:e95240.
9. Yu DD, Wu Y, Zhang XH, Lv MM, Chen WX, Chen X, Yang SJ, Shen H, Zhong SL, Tang JH and Zhao JH. Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222. Tumour Biol. 2015.
10. Mao L, Li J, Chen WX, Cai YQ, Yu DD, Zhong SL, Zhao JH, Zhou JW and Tang JH. Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs. Tumour Biol. 2015.
11. Zhong S, Ma T, Zhang X, Lv M, Chen L, Tang J and Zhao J. MicroRNA expression profiling and bioinformatics analysis of dysregulated microRNAs in vinorelbineresistant breast cancer cells. Gene. 2015; 556:113-118.
12. Lv MM, Zhu XY, Chen WX, Zhong SL, Hu Q, Ma TF, Zhang J, Chen L, Tang JH and Zhao JH. Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour Biol. 2014; 35:10773-10779.
13. Zhong S, Li W, Chen Z, Xu J and Zhao J. miR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene. 2013; 531:8-14.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT and Christian MC. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute. 2000; 92:205-216.
15. Agarwal V, Bell GW, Nam JW and Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015; 4.
16. Wong N and Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015; 43:D146-152.
17. Huang da W, Sherman BT and Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009; 37:1-13.
18. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, Pico AR, Bader GD and Ideker T. A travel guide to Cytoscape plugins. Nat Methods. 2012; 9:1069-1076.
19. Lowry MC, Gallagher WM and O'Driscoll L. The Role of Exosomes in Breast Cancer. Clin Chem. 2015; 61:1457-1465.
20. Wang S, Li W, Xue Z, Lu Y, Narsinh K, Fan W, Li X, Bu Q, Wang F, Liang J, Wu K and Cao F. Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin. Mol Carcinog. 2013; 52:900-907.
21. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D and Vadgama JV. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Molecular Cancer Research. 2012; 10:1597-1606.
22. Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ and Tyner JW. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. Cancer Res. 2015; 75:880-891.
23. Block M, Grundker C, Fister S, Kubin J, Wilkens L, Mueller MD, Hemmerlein B, Emons G and Gunthert AR. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. Int J Oncol. 2012; 41:1845-1854.